Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

FDA approves HEMLIBRA for treatment of hemophilia A

Chugai Pharmaceutical Co., Ltd. announced today that the U.S. Food and Drug Administration (FDA) has approved HEMLIBRA (US generic name: emicizumab-kxwh), a treatment for hemophilia A created by Chugai, for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children, ages newborn and older, with hemophilia A without factor VIII inhibitors, administered once weekly, every two weeks, or every four weeks.

5 Oct 2018

Vaxart to present new data from Phase 2 Challenge Study of H1 influenza oral tablet vaccine

Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced it will present new data from the Phase 2 Challenge Study of its H1 influenza oral tablet vaccine at IDWeek 2018 in San Francisco on Saturday, October 6, 2018.

4 Oct 2018

Wits doctors transplant liver from HIV positive mother to her child with end-stage liver disease

This was the ethical dilemma faced by doctors at Wits Donald Gordon Medical Centre to save a child's life.

4 Oct 2018

Special glowing paper strip as rapid, reliable test for infectious diseases

Researchers from Eindhoven University of Technology (The Netherlands) and Keio University (Japan) present a practicable and reliable way to test for infectious diseases.

3 Oct 2018

A Single Platform to Sequence All Monoclonal Antibody Proteins

Having a single platform to sequence all monoclonal antibody proteins provides researchers with key information for research, development and drug discovery

From Rapid Novor Inc 3 Oct 2018

Panel of human antibodies developed to neutralize black mamba snake toxin

IONTAS Limited, a leader in the discovery and optimisation of fully human antibodies, today announced a collaborative paper published in Nature Communications with the Technical University of Denmark, and the Instituto Clodomiro Picado of the University of Costa Rica describing the development of a panel of human antibodies that neutralise elements of black mamba snake toxin in an in vivo model.

3 Oct 2018

New way of using natural killer cells makes immunotherapy viable to more patients

Immunotherapy is making headlines for saving the lives of hundreds of cancer patients including former President Jimmy Carter. But many of these therapies, only work for a small portion of people who have a specific molecule called PDL1 in their cancer makeup.

3 Oct 2018

Phase 3 ECHELON-2 clinical trial evaluating ADCETRIS plus CHP meets primary endpoint

Seattle Genetics, Inc. and Takeda Pharmaceutical Company Limited announced today that the phase 3 ECHELON-2 clinical trial met its primary endpoint.

1 Oct 2018

New project identifies immune checkpoint inhibition as potential treatment for angiosarcomas

Angiosarcoma Project, a patient-partnered genomics study, identified immune checkpoint inhibition as a potential treatment option for patients with angiosarcomas of the head, face, neck, or scalp, according to data presented at the fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference.

1 Oct 2018

New project aims to develop strategies for more durable animal-derived heart valves

Animal-derived heart valves are preferred to mechanical ones for valve-replacement heart surgery because they are more biocompatible and do not require a life-changing regime of anticoagulant drugs.

29 Sep 2018

Broadly neutralizing antibodies offer a new approach to treating HIV infection

A new generation of broadly neutralizing antibodies provides a novel approach to treating HIV infection.

28 Sep 2018

CNL, TRIUMF team up to enable revolutionary cancer treatment

TRIUMF, Canada's particle accelerator center, and Canadian Nuclear Laboratories, Canada's premier nuclear science and technology organization, are pleased to announce that they have agreed to pursue a strategic partnership around the commercial production of Actinium-225, a rare medical isotope that has the potential to serve as the basis of new ground-breaking cancer treatments.

28 Sep 2018

Cidara initiates Phase 3 clinical trial to evaluate efficacy, safety of rezafungin to treat invasive candidiasis

Cidara Therapeutics, Inc., a biotechnology company developing novel anti-infectives including immunotherapies, today announced that the first trial site has been activated for ReSTORE, a Phase 3 clinical trial evaluating the efficacy and safety of the company's lead antifungal, rezafungin, to treat candidemia and invasive candidiasis.

27 Sep 2018

Scientists discover most important target of MRSA bacterial toxin and ways to neutralize it

For patients diagnosed with a Staphylococcus aureus infection, often referred to as a staph or MRSA infection, every minute counts.

27 Sep 2018

New approach to vaccine development and improved surveillance could help target deadly diseases

Scientists hope that a new approach to vaccine development, combined with improved surveillance of potential future threats of outbreak, could help to massively reduce the impact of deadly diseases such as Ebola, Marburg and Lassa fever.

26 Sep 2018

UC Davis researchers take critical step in developing more effective Salmonella vaccine

UC Davis researchers announce in the Proceedings of the National Academy of Sciences this week a breakthrough in understanding which cells afford optimal protection against Salmonella infection--a critical step in developing a more effective and safe vaccine against a bacterium that annually kills an estimated one million people worldwide.

25 Sep 2018

TU Wien develops new remedy for celiac disease

Celiac disease is a fairly common disease, affecting one to two percent of the European population. It is expressed as a hypersensitivity to gluten, a protein found in cereals such as wheat, barley or rye.

24 Sep 2018

Alexion announces positive results from Phase 3 PREVENT study of Soliris in patients with NMOSD

Alexion Pharmaceuticals, Inc. today announced positive topline results from the Phase 3 PREVENT study of Soliris in patients with anti-aquaporin-4 auto antibody-positive neuromyelitis optica spectrum disorder.

24 Sep 2018

ADCETRIS drug receives approval in Japan as frontline treatment option for Hodgkin lymphoma

Seattle Genetics, Inc. today announced that its collaborator, Takeda Pharmaceutical Company Limited, has received approval from the Japanese Ministry of Health, Labour and Welfare for ADCETRIS (brentuximab vedotin) in combination with doxorubicin, vinblastine and dacarbazine as a frontline treatment option for CD30-positive Hodgkin lymphoma patients in Japan.

24 Sep 2018

Biogen and Eisai announce results of LTE Phase 1b study of aducanumab for treating MCI

Biogen and Eisai Co., Ltd. announced results from a recent analysis of the ongoing long-term extension Phase 1b study of aducanumab, an investigational treatment for mild cognitive impairment due to Alzheimer's disease and mild AD dementia.

24 Sep 2018

Antibody News and Research

Further Reading

FDA approves HEMLIBRA for treatment of hemophilia A

Vaxart to present new data from Phase 2 Challenge Study of H1 influenza oral tablet vaccine

Wits doctors transplant liver from HIV positive mother to her child with end-stage liver disease

Special glowing paper strip as rapid, reliable test for infectious diseases

A Single Platform to Sequence All Monoclonal Antibody Proteins

Panel of human antibodies developed to neutralize black mamba snake toxin

New way of using natural killer cells makes immunotherapy viable to more patients

Phase 3 ECHELON-2 clinical trial evaluating ADCETRIS plus CHP meets primary endpoint

New project identifies immune checkpoint inhibition as potential treatment for angiosarcomas

New project aims to develop strategies for more durable animal-derived heart valves

Broadly neutralizing antibodies offer a new approach to treating HIV infection

CNL, TRIUMF team up to enable revolutionary cancer treatment

Cidara initiates Phase 3 clinical trial to evaluate efficacy, safety of rezafungin to treat invasive candidiasis

Scientists discover most important target of MRSA bacterial toxin and ways to neutralize it

New approach to vaccine development and improved surveillance could help target deadly diseases

UC Davis researchers take critical step in developing more effective Salmonella vaccine

TU Wien develops new remedy for celiac disease

Alexion announces positive results from Phase 3 PREVENT study of Soliris in patients with NMOSD

ADCETRIS drug receives approval in Japan as frontline treatment option for Hodgkin lymphoma

Biogen and Eisai announce results of LTE Phase 1b study of aducanumab for treating MCI

Immunology eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo